Analysts are estimating that Biogen will report an earnings per share (EPS) of $3.89. The announcement from Biogen is eagerly ...

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges ...

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

Fintel reports that on November 3, 2025, Bernstein maintained coverage of Biogen (NasdaqGS:BIIB) with a Market Perform ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed ...

Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% ...

Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.

Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to ...

Discover Biogen's Q3 2025 earnings: 67% launch product growth, strategic pipeline expansion, and updated guidance amid evolving market dynamics.